EP
SUPN icon

Eversept Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Eversept Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-105,581
Closed -$3.82M – 69
2024
Q4 		$3.82M Buy
+105,581
New +$3.72M 0.34% 47

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Eversept Partners's SUPN Position: Q1 2025 in Review

Eversept Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 105,581 shares — an estimated $3.82M sold.

Eversept Partners first reported a position in SUPN in Q4 2024 and held it in 1 quarter. The position peaked at $3.82M in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Eversept Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eversept Partners sold 105,581 Supernus Pharmaceuticals shares in Q1 2025, an estimated $3.82M.
  • Eversept Partners first reported a position in Supernus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Eversept Partners's Supernus Pharmaceuticals position peaked at $3.82M in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.